Radiation dosimetry estimates of 18F-alfatide II based on whole-body PET imaging of mice

• We demonstrated a proper mice model to estimate human radiation dosimetry.
• This is the first paper to estimate human radiation dosimetry of 18F-alfatide II.
• Estimated effective dose are in the range of routine nuclear medicine studies.

We estimated the dosimetry of 18F-alfatide II with the method established by MIRD based on biodistribution data of mice. Six mice (three females and three males) were scanned for 160 min on an Inveon MicroPET/CT scanner after injection of 18F-alfatide II via tail vein. Eight source organs were delineated on the CT images and their residence times calculated. The data was then converted to human using scaling factors based on organ and body weight. The absorbed doses for human and the resulting effective dose were computed by OLINDA 1.1 software. The highest absorbed doses was observed in urinary bladder wall (male 0.102 mGy/MBq, female 0.147 mGy/MBq); and the lowest one was detected in brain (male 0.0030 mGy/MBq, female 0.0036). The total effective doses were 0.0127 mSv/MBq for male and 0.0166 mSv/MBq for female, respectively. A 370-MBq injection of 18F-alfatide II led to an estimated effective dose of 4.70 mSv for male and 6.14 mSv for female. The potential radiation burden associated with 18F-alfatide II/PET imaging therefore is comparable to other PET examinations.

Figure optionsDownload as PowerPoint slide